UNSPSC 51312207: Azatadine maleate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H22N2.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F3Q391WTX7, chemically known as 6,11-dihydro-11-(1-methyl-4-piperidylidene)-5h-benzo(5,6)cyclohepta(1,2-b)pyridine but more generally known as azatadine maleate, which bears US NIH Compound Identifier 19861. European Medicines Agency schedules Azatadine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00640MIG.

UNSPSC 51312207 Azatadine maleate is a Commodity code that nominally covers a single antihistamine active pharmaceutical ingredient, but recent state and local opportunities tagged to this code show minimal alignment with that specific product. The recent opportunities instead reflect broader pharmaceutical procurement activity: naloxone and drug deactivation systems, direct-to-manufacturer prescription program capability, and multi-source generic pharmaceuticals and OTC products distributed through authorized wholesalers. State and local buyers using this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance). The mismatch between the code's nominal scope and actual recent solicitations suggests either tagging inconsistency or that this Commodity code is being used as a catch-all for pharmaceutical procurement that does not fit narrower product-specific codes.

Recent activity spans Florida, Texas, and Minnesota. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager relationships. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted an RFP (S1070000015802) on January 20, 2026, to establish contracts for generic multi-source pharmaceuticals and OTC products supplied through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026, and awards effective July 1, 2026. The Minnesota procurement emphasizes price competitiveness (75 percent of evaluation weight), cGMP and DSCSA compliance, and relationships with at least two of three authorized wholesalers. The code shows activity from health agencies and cooperative purchasing vehicles, but the limited recent opportunities and category misalignment suggest this Commodity code warrants close attention to actual solicitation language before pursuing.